<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008992</url>
  </required_header>
  <id_info>
    <org_study_id>CV019-002</org_study_id>
    <nct_id>NCT04008992</nct_id>
  </id_info>
  <brief_title>An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BMS-986259 in Healthy Participants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and
      effectiveness of the drug amongst different conditions and populations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">August 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs leading to discontinuation</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in vital signs</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in ECG (electrocardiogram)</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in physical examinations</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration(Cmax)- Part A SAD</measure>
    <time_frame>up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration(Tmax)- Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Lz)-Part A SAD</measure>
    <time_frame>up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-HALF)- Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration(AUC(0-T)- Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time(AUC(INF)-Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance(CL/F)-Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase(Vz/F)- Part A SAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration(Cmax)-Part B and Part C MAD</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>For day 1 , day 13 and day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration(Tmax)-Part B and Part C MAD</measure>
    <time_frame>Up tp 7 weeks</time_frame>
    <description>For day 1, day 13 and day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval(AUC(TAU)- Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For day 1 and day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration(AUC(0-T)-Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (Lz)-Part B and Part C MAD</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>For day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-HALF)- Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance(CL/F)-Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase(Vz/F)- Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio Cmax (AR(Cmax)-Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>For day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio AUC(TAU) (AR(AUC[TAU])- Part B and Part C MAD</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>for day 14</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A SAD - A1 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD - A2 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD- A3 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD- A4 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD - A5 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A SAD- A6 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD- B1 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD - B2 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD - B3 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD - B4 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C JMAD - C1 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C JMAD - C2 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Multiple Ascending Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C JMAD - C3 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Multiple Ascending Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986259</intervention_name>
    <description>Single and Multiple ascending dose from Dose 1 to Dose 5</description>
    <arm_group_label>Part A SAD - A1 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A2 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A5 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A3 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A4 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A6 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B2 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B3 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B4 Cohort</arm_group_label>
    <arm_group_label>Part B MAD- B1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C2 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C3 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BMS-986259</description>
    <arm_group_label>Part A SAD - A1 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A2 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A5 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A3 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A4 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A6 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B2 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B3 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B4 Cohort</arm_group_label>
    <arm_group_label>Part B MAD- B1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C2 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C3 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>P-Aminohippurate</intervention_name>
    <description>Diagnostic Agent</description>
    <arm_group_label>Part A SAD - A1 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A2 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A5 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A3 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A4 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A6 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B2 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B3 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B4 Cohort</arm_group_label>
    <arm_group_label>Part B MAD- B1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C2 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C3 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Diagnostic Agent</description>
    <arm_group_label>Part A SAD - A1 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A2 Cohort</arm_group_label>
    <arm_group_label>Part A SAD - A5 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A3 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A4 Cohort</arm_group_label>
    <arm_group_label>Part A SAD- A6 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B2 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B3 Cohort</arm_group_label>
    <arm_group_label>Part B MAD - B4 Cohort</arm_group_label>
    <arm_group_label>Part B MAD- B1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C1 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C2 Cohort</arm_group_label>
    <arm_group_label>Part C JMAD - C3 Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants with a body mass Index (BMI) of 18.0 kg/m^2 - 30.0 kg/m^2.

          -  Males and females not of child bearing potential.

          -  Participants in the Japanese Cohorts in Part C must be first-generation Japanese (born
             in Japan, not living outside of Japan for more than 10 years, and both parents are
             ethnically Japanese.)

        Exclusion Criteria:

          -  Any previous dosing in another cohort in the current study or participation in an
             investigational drug within 2 months prior to (the first) drug administration in the
             current study.

          -  Any Significant Acute or Chronic medical Illness, major surgery in 12 months, or so
             smoking or used smoking cessation in 3 months.

          -  Inability to be venipunctured and/or tolerate venous access. ,abnormalities in
             hemoglobin or positive screen for hepatitis C, Hepatitis B, Human Immunodeficiency
             Virus (HIV), including hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA Health Sciences - Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Pharmacology</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

